Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality


Kevin Outterson and colleagues outline a model to address access, conservation, and innovation of antibiotics.


Vyšlo v časopise: Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality. PLoS Med 13(6): e32767. doi:10.1371/journal.pmed.1002043
Kategorie: Essay
prolekare.web.journal.doi_sk: 10.1371/journal.pmed.1002043

Souhrn

Kevin Outterson and colleagues outline a model to address access, conservation, and innovation of antibiotics.


Zdroje

1. The White House. Executive Order—Combating Antibiotic-Resistant Bacteria [Internet]. 2014 [cited 2015 Sep 1]. https://www.whitehouse.gov/the-press-office/2014/09/18/executive-order-combating-antibiotic-resistant-bacteria

2. The White House. National Action Plan for Combating Antibiotic-Resistant Bacteria [Internet]. 2015 Mar [cited 2015 Sep 1]. https://www.whitehouse.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf

3. WHO. Global action plan on antimicrobial resistance. 68th World Health Assembly. [Internet]. Geneva, Switzerland; 2015 [cited 2015 Oct 9]. http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_R7-en.pdf

4. The Review on Antimicrobial Resistance, chaired by Jim O’Neill. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations [Internet]. 2014; [cited 2015 Sep 10]. http://www.jpiamr.eu/wp-content/uploads/2014/12/AMR-Review-Paper-Tackling-a-crisis-for-the-health-and-wealth-of-nations_1-2.pdf

5. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011 Jan;24(1):71–109. doi: 10.1128/CMR.00030-10 21233508

6. Coates ARM, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br J Pharmacol. 2011 May;163(1):184–94. doi: 10.1111/j.1476-5381.2011.01250.x 21323894

7. The Review on Antimicrobial Resistance, chaired by Jim O’Neill. Securing new drugs for future generations: The pipeline for antibiotics [Internet]. 2015 [cited 2015 Sep 1]. http://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf

8. WHO. WHO’s first global report on antibiotic resistance reveals serious, worldwide threat to public health [Internet]. News release; 2014 [cited 2015 Oct 9]. http://www.who.int/mediacentre/news/releases/2014/amr-report/en/

9. Outterson K. New business models for sustainable antibiotics [Internet]. London: Royal Institute of International Affairs; 2014 [cited 2014 Oct 18]. http://www.chathamhouse.org/sites/default/files/public/Research/Global%20Health/0214SustainableAntibiotics.pdf

10. So AD, Gupta N, Brahmachari SK, Chopra I, Munos B, Nathan C, et al. Towards new business models for R&D for novel antibiotics. Drug Resist Updat. 2011 Apr;14(2):88–94. doi: 10.1016/j.drup.2011.01.006 21439891

11. Clift C, Gopinathan U, Morel C, Outterson K, Røttingen J-A, So A. Towards a New Global Business Model for Antibiotics. Delinking Revenues from Sales. Report from the Chatham House Working Group on New Antibiotic Business Models. London: The Royal Institute of International Affairs; 2015. https://www.chathamhouse.org/sites/files/chathamhouse/field/field_document/20151009NewBusinessModelAntibioticsCliftGopinathanMorelOuttersonRottingenSo.pdf

12. Hoffman SJ, Outterson K, Røttingen J-A, Cars O, Clift C, Rizvi Z, et al. An international legal framework to address antimicrobial resistance. Bull World Health Organ. 2015 Feb 1;93(2):66. doi: 10.2471/BLT.15.152710 25883395

13. Consultative Expert Working Group on Research and Development. Research and development to meet health needs in developing countries: Strengthening global financing and coordination. Geneva, Switzerland: World Health Organization; 2012.

14. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014 Aug;14(8):742–50. doi: 10.1016/S1473-3099(14)70780-7 25022435

15. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. 2003 Oct;6(5):427–30. 14572532

16. Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis. 2016 April;16(4):500–505. doi: 10.1016/S1473-3099(15)00500-9 27036356

17. Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005 Feb 12;365(9459):579–87. 15708101

18. Love J, Hubbard T. Prizes for innovation of new medicines and vaccines. Ann Health Law. 2009;18(2):155–86, 8 p. preceding i. 21950238

19. Hoen E ‘t, Berger J, Calmy A, Moon S. Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Int AIDS Soc. 2011;14:15. doi: 10.1186/1758-2652-14-15 21439089

20. Megget K. Fixing the broken antibiotics business model [Internet]. Royal Society of Chemistry; 2016 [cited 2016 Feb 26]. http://www.rsc.org/chemistryworld/2016/01/antibiotics-resistance-business-model-commercial-strategies

21. Cecchini M, Langer J, Slawomirski L. Antimicrobial resistance in G7 countries and beyond: Economic Issues, Policies and Options for Action [Internet]. Organisation for Economic Co-operation and Development; 2015 Sep [cited 2016 Feb 26]. http://www.oecd.org/els/health-systems/Antimicrobial-Resistance-in-G7-Countries-and-Beyond.pdf

22. Hoffman SJ, Outterson K. What Will It Take to Address the Global Threat of Antibiotic Resistance? J Law Med Ethics. 2015;43(2):363–8. doi: 10.1111/jlme.12253 26242959

23. Hoffman SJ, Caleo GM, Daulaire N, Elbe S, Matsoso P, Mossialos E, et al. Strategies for achieving global collective action on antimicrobial resistance. Bull World Health Organ. 2015 Dec 1;93(12):867–76. doi: 10.2471/BLT.15.153171 26668439

24. Årdal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M, Ranganathan N, et al. International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet. 2016 Jan 16;387(10015):296–307. doi: 10.1016/S0140-6736(15)00470-5 26603920

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2016 Číslo 6
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Hereditární TTR amyloidóza – vzácné, nebo jen neodhalené onemocnění? 2. díl
nový kurz

Eozinofilní granulomatóza s polyangiitidou

Betablokátory a Ca antagonisté z jiného úhlu
Autori: prof. MUDr. Michal Vrablík, Ph.D., MUDr. Petr Janský

Autori: doc. MUDr. Petr Čáp, Ph.D.

Farmakoterapie akutní a chronické bolesti

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Nemáte účet?  Registrujte sa

Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa